Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FT500 · 1 trial · 18 indications
The incidence of participants with DLTs within each assessed dose level cohort to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD).
| Arm | Type | Description |
|---|---|---|
| FT500 Monotherapy | EXPERIMENTAL | FT500 administered once weekly for 3 weeks as a monotherapy |
| FT500 in Combination with Immune Checkpoint Inhibitor | EXPERIMENTAL | FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab. |
| FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor | EXPERIMENTAL | FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab. |
| Name | Type | Description |
|---|---|---|
| FT500 | DRUG | FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy |
| Nivolumab | DRUG | Immune Checkpoint Inhibitor |
| Pembrolizumab | DRUG | Immune Checkpoint Inhibitor |
| Atezolizumab | DRUG | Immune Checkpoint Inhibitor |
| Cyclophosphamide | DRUG | Lympho-conditioning agent |
| Fludarabine | DRUG | Lympho-conditioning agent |
| IL-2 | DRUG | Biologic response modifier |
Inclusion Criteria: 1\. Diagnosis of the following, as per Regimen Cohort: 1A. Regimen A: FT500 Monotherapy (Dose Escalation): An advanced solid tumor malignancy, including lymphoma, in a participant who has failed or refused available FDA-approved therapies and is now a candidate for salvage ther...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
FT500 is an investigational cell therapy being studied for the treatment of advanced solid tumors. It is being evaluated as a monotherapy and in combination with immune checkpoint inhibitors in patients with various advanced solid tumors, including gastric cancer, colorectal cancer, head and neck cancer, and melanoma.
FT500 is an induced pluripotent stem cell-derived natural killer cell product. It is designed to target and kill tumor cells and to enhance the activity of immune checkpoint inhibitors by promoting an anti-tumor immune response in the tumor microenvironment.
FT500 is being developed by Fate Therapeutics, Inc., a biopharmaceutical company. Fate Therapeutics is publicly traded on the Nasdaq under the ticker symbol FATE.
FT500 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 trial has been completed, and the drug is no longer in active clinical testing.
FT500 has been studied in one clinical trial, NCT03841110, titled 'FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors.' This Phase 1 trial was conducted in the United States and enrolled 37 patients with advanced solid tumors.
FT500 is a distinct investigational cell therapy developed by Fate Therapeutics. It is not known to be the same as any other approved or investigational drug. Its unique mechanism involves induced pluripotent stem cell-derived natural killer cells.